NEW YORK (GenomeWeb News) – Metamark Genetics today announced that Massachusetts has licensed the company's laboratory as it prepares to launch its prognostic assay for managing patients with prostate cancer.

The lab in Cambridge, Mass. is CLIA-certified, but a handful of states require additional regulatory approval before certain tests can be performed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.